bioAffinity Technologies Inc

bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies will present at the invitation-only Cleveland Clinic annual symposium on advances in early-stage lung cancer detection.

bioAffinity Technologies Presents at Cleveland Clinic Lung Cancer Symposium

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies rings the Nasdaq Stock Market closing bell this afternoon to commemorate the Company's 2022 initial public offering (IPO).

bioAffinity Technologies to Ring Nasdaq Closing Bell Today

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and 12 months ended December 31, 2022.

bioAffinity Technologies Reports Fourth Quarter and Full Year 2022 Financial Results

SAN ANTONIO--(BUSINESS WIRE)-- #CyPathLung--bioAffinity's scientific paper on proprietary compensation beads used in the CyPath® Lung test is published in peer-reviewed journal.

bioAffinity Technologies Announces Publication of Peer-Reviewed Paper on Proprietary Beads Used in CyPath® Lung for Noninvasive Detection of Early-Stage Lung Cancer

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.

bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications and federal public affairs, as bioAffinity Technologies' Director of Communications, and the marketing and advertising firms of Havas Health & You and Trinity Life Sciences to help build the CyPath® Lung brand and position it for success in the cancer diagnostics sector.

bioAffinity Technologies Appoints Julie Anne Overton Director of Corporate Communications

SAN ANTONIO--( BUSINESS WIRE )--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing results of the Company's clinical trial for its non-invasive diagnostic CyPath® Lung in Respiratory Research, one of the leading peer-reviewed open access journals in the field of respiratory medicine.

bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research

SAN ANTONIO--( BUSINESS WIRE )--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for Treating Cancer” for the targeted delivery of novel cancer treatments. A Notice of Allowance is issued after the USPTO makes a determination that a patent should be granted for the claimed invention. The U.S. patent will issue to the Company's wholly owned subsidiary OncoSelect and grant protection to 2037.

bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments

NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) Click Here to view full Argus Equity Research Report. COMPANY HIGHLIGHTS: Excerpts (as conveyed by Argus Analyst Steve Silver) include: BIAF:  A Potential Advance in the Early Detection of Cancer In our view, bioAffinity is well positioned to establish its CyPath® Lung test as a cost-effective, non-invasive tool to aid in the early detection of lung cancer, which is among the most common and deadly forms of cancer.

Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF)

SAN ANTONIO--( BUSINESS WIRE )--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, as well as targeted cancer treatment, today announced that they have made a key promotion and additions to their staff.

bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench

SAN ANTONIO--( BUSINESS WIRE )--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment, today announced that David Elzi, Ph.D., bioAffinity Vice President of Research, will discuss his research into a possible mechanism by which the knock down of two genes kills cancer cells with little or no effect on normal cells at Cell Bio, a joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), in Washington, D.C., on Dec. 3-7, 2022. Dr. Elzi's research supports the Company's development of broad-spectrum cancer therapeutics.

bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting

SAN ANTONIO--( BUSINESS WIRE )--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive diagnosis of early-stage cancer and diseases of the lung, and targeted cancer treatment, today reported its financial results for the third quarter of 2022 and provided a business update.

bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--Sheila Habib, MD, and David Hill, MD, leaders in the lung cancer field, join the bioAffinity Technologies Scientific and Medical Advisory Board.

bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company's Scientific and Medical Advisory Board

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced that the Company will host a conference call and audio webcast on Monday, Nov. 14, 2022, at 8 a.m.

bioAffinity Technologies to Report Third Quarter 2022 Financial Results

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People's Republic of China awarded a Certificate of Patent to the Company's wholly owned subsidiary OncoSelect® for its patent “Porphyrin Compounds and Compositions Useful for Treating Cancer” that is directed to novel compounds in which porphyrins are conjugated to chemotherapeutics for selective delivery of cancer treatment.

bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies presents results from flow cytometry analysis to detect diseases of the lung at CHEST Conference.

bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference

Avalon GloboCare Corp

Ocular Therapeutix

What happened in the stock market today and Penny stocks to watch this week. The post Stock Market Today: What Happened & 3 Penny Stocks To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Stock Market Today: What Happened & 3 Penny Stocks To Watch Now

Kinross Gold

MannKind

Transocean

Uranium Energy

Penny sleeper stocks can offer tremendous risks to investors. However, much like any other speculative investment category, it's possible that traders can still generate incredible, perhaps life changing profits.

7 Penny Sleeper Stocks to Buy Before Wall Street Wakes Up

Sobr Safe Inc

TOP Ships

Are these penny stocks on your watchlist today? The post Penny Stocks to Buy in a Bear Market?

Penny Stocks to Buy in a Bear Market? 3 to Watch Right Now

Early diagnosis specialist BioAffinity (NASDAQ: BIAF ) spiked 60% on Wednesday morning before paring back some gains in the afternoon to around 40% up. Investors piled into BIAF stock upon the underlying company disclosing the receipt of approximately $7.7 million in additional gross proceeds from its initial public offering (IPO).

Why Is BioAffinity (BIAF) Stock Up 40% Today?

SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies receives additional $7.7M from exercise of warrants, increasing total capital from IPO to approximately $15.6M

bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M

Source: CI Photos / Shutterstock.com BioAffinity (NASDAQ: BIAF ) stock is rising higher on Wednesday after the cancer diagnostic company announced the publication of its research in PLOS ONE . This was published under the title Sputum analysis by flow cytometry; an effective platform to analyze the lung environment.

What Is Going on With bioAffinity (BIAF) Stock Today?

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--bioAffinity publishes peer-reviewed results in PLOS ONE for evaluating lung health by using high-throughput flow cytometry to analyze sputum.

bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE

JERSEY CITY, N.J. , Sept. 6, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today bioAffinity Technologies, Inc. ("bioAffinity" or the "Company") (NASDAQ: BIAF, BIAFW), a cancer diagnostics company that develops noninvasive, early-stage diagnostics to detect cancer and diseases of the lung, has completed its previously announced initial public offering ("IPO") of 1,282,600 units, each consisting of one share of common stock, one tradeable warrant to purchase one share of common stock at an exercise price of $7.35 per share, and one non-tradeable warrant to purchase one share of common stock at an exercise price of $7.656 per share, for aggregate gross proceeds of approximately $7.8 million, prior to deducting underwriting discounts, commissions, and other offering expenses.

WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering

SAN ANTONIO--(BUSINESS WIRE)-- #IPO--Cancer diagnostic company bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), announces closing of $7.8 million IPO.

News for bioAffinity Technologies Inc Stock (BIAF)